JP2010501483A - 乳酸塩及び過分極１３ｃ−ピルビン酸塩を含むイメージング剤 - Google Patents

乳酸塩及び過分極１３ｃ−ピルビン酸塩を含むイメージング剤 Download PDF

Info

Publication number
JP2010501483A
JP2010501483A JP2009524574A JP2009524574A JP2010501483A JP 2010501483 A JP2010501483 A JP 2010501483A JP 2009524574 A JP2009524574 A JP 2009524574A JP 2009524574 A JP2009524574 A JP 2009524574A JP 2010501483 A JP2010501483 A JP 2010501483A
Authority
JP
Japan
Prior art keywords
imaging
pyruvate
imaging agent
lactate
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009524574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501483A5 (https=
Inventor
ブリンドル，ケビン・エム
デイ，サミュエル・エヴァン
Original Assignee
ジーイー・ヘルスケア・アクスイェ・セルスカプ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーイー・ヘルスケア・アクスイェ・セルスカプ filed Critical ジーイー・ヘルスケア・アクスイェ・セルスカプ
Publication of JP2010501483A publication Critical patent/JP2010501483A/ja
Publication of JP2010501483A5 publication Critical patent/JP2010501483A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP2009524574A 2006-08-18 2007-08-17 乳酸塩及び過分極１３ｃ−ピルビン酸塩を含むイメージング剤 Withdrawn JP2010501483A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20063701 2006-08-18
PCT/NO2007/000287 WO2008020765A2 (en) 2006-08-18 2007-08-17 Imaging medium comprising lactate and hyperpolarised 13c-pyruvate

Publications (2)

Publication Number Publication Date
JP2010501483A true JP2010501483A (ja) 2010-01-21
JP2010501483A5 JP2010501483A5 (https=) 2010-08-26

Family

ID=38719770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009524574A Withdrawn JP2010501483A (ja) 2006-08-18 2007-08-17 乳酸塩及び過分極１３ｃ−ピルビン酸塩を含むイメージング剤

Country Status (6)

Country Link
US (1) US20100178249A1 (https=)
EP (1) EP2051739A2 (https=)
JP (1) JP2010501483A (https=)
KR (1) KR20090052859A (https=)
CN (1) CN101505802A (https=)
WO (1) WO2008020765A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504349A (ja) * 2009-09-10 2013-02-07 ジーイー・ヘルスケア・リミテッド 過分極１３ｃ−フルクトースを用いる１３ｃ−ｍｒ検出

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010230330B2 (en) * 2009-04-02 2015-06-25 Ge Healthcare Limited Use of a magnetic resonance imaging medium comprising hyperpolarized 13C pyruvate for the detection of inflammation or infection
JP5879333B2 (ja) 2010-05-03 2016-03-08 ジーイー・ヘルスケア・リミテッド Ｌｄｈ活性を決定するための過分極乳酸塩造影剤
WO2012145733A1 (en) 2011-04-22 2012-10-26 Vanderbilt University Para-hydrogen polarizer
US10265421B2 (en) 2013-01-31 2019-04-23 Bracco Imaging S.P.A. Hyperpolarized esters as metabolic markers in MR
DK3058375T3 (en) * 2013-10-15 2019-04-08 Univ Muenchen Tech pH Biosensors based on compounds made of pyruvic acid for magnetic resonance imaging and spectroscopy and their applications
EP2863229A1 (en) 2013-10-15 2015-04-22 Technische Universität München pH-biosensors based on compounds with pH-sensitive enolic groups for magnetic resonance imaging and spectroscopy and their uses
KR101516634B1 (ko) * 2014-07-09 2015-05-06 연세대학교 산학협력단 13c-자기공명분광영상을 이용한 암 환자의 치료 예후를 예측하는 방법
WO2017136700A1 (en) 2016-02-05 2017-08-10 The Trustees Of The University Of Pennsylvania Non-nutritive sweeteners and polyols as imaging agents
US10901058B2 (en) 2016-02-05 2021-01-26 The Trustees Of The University Of Pennsylvania Chemical exchange saturation transfer (CEST) imaging of lactate (LATEST)
KR101939454B1 (ko) * 2017-03-21 2019-01-16 전남대학교산학협력단 생체 내 과분극화 c13 피루베이트 자기공명분광법을 이용하여 새로운 정량적 생체지표를 통한 비알코올성 지방간질환 진단 방법
KR102457806B1 (ko) * 2020-11-02 2022-10-28 전남대학교 산학협력단 과분극화된 13c 피루베이트 자기공명분광영상을 이용한 만성 간질환의 예후 판단을 위한 정보제공방법
WO2024254159A1 (en) * 2023-06-05 2024-12-12 The Regents Of The University Of California Compositions and method for diagnosing and treating alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329208B1 (en) * 1997-07-16 2001-12-11 Board Of Regents, The University Of Texas System Methods for determining gluconeogenesis, anapleurosis and pyruvate recycling
EP1302465A1 (en) * 2001-10-11 2003-04-16 BRACCO IMAGING S.p.A. Enhanced substrate imaging by reversible binding to a paramagnetic complex
WO2006011810A2 (en) * 2004-07-30 2006-02-02 Ge Healthcare As Mr imaging method for the discrimination between healthy and tumour tissue
WO2006054903A2 (en) * 2004-11-19 2006-05-26 Ge Healthcare As Method of cardiac imaging with the use of hyperpolarized 13 c-pyruvate
US20100233096A1 (en) * 2006-03-29 2010-09-16 Lerche Mathilde H Method to produce hyperpolarised carboxylates and sulphonates
CN101506679B (zh) * 2006-08-18 2013-03-06 通用电气医疗集团股份有限公司 细胞死亡的13c-mr成像或波谱分析

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504349A (ja) * 2009-09-10 2013-02-07 ジーイー・ヘルスケア・リミテッド 過分極１３ｃ−フルクトースを用いる１３ｃ−ｍｒ検出

Also Published As

Publication number Publication date
KR20090052859A (ko) 2009-05-26
WO2008020765A3 (en) 2008-04-24
US20100178249A1 (en) 2010-07-15
WO2008020765A2 (en) 2008-02-21
CN101505802A (zh) 2009-08-12
EP2051739A2 (en) 2009-04-29

Similar Documents

Publication Publication Date Title
JP5456256B2 (ja) 心臓イメージング法
JP2010501483A (ja) 乳酸塩及び過分極１３ｃ−ピルビン酸塩を含むイメージング剤
JP2008508023A5 (https=)
JP5363320B2 (ja) 細胞死の１３ｃ−ｍｒイメージング又は分光法
EP2180902B1 (en) Imaging medium comprising hyperpolarised ¹³c-acetate and use thereof
JP5868311B2 (ja) 炎症又は感染の検出のための過分極１３ｃピルビン酸塩を含む磁気共鳴造影媒体の使用
JP5879333B2 (ja) Ｌｄｈ活性を決定するための過分極乳酸塩造影剤
US8968703B2 (en) 13C-MR detection using hyperpolarised 13C-fructose
JP2011511775A (ja) 過分極１３ｃ−アラニンを含むｍｒ造影剤、又は画像媒体、及びそのような画像媒体を使用する画像検査法
Lerche et al. Method of Cardiac Imaging

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100706

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100706

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100706

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20111115

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20111206